PE20230488A1 - Inhibidores macrociclicos de las peptidilarginina deiminasas - Google Patents
Inhibidores macrociclicos de las peptidilarginina deiminasasInfo
- Publication number
- PE20230488A1 PE20230488A1 PE2022002498A PE2022002498A PE20230488A1 PE 20230488 A1 PE20230488 A1 PE 20230488A1 PE 2022002498 A PE2022002498 A PE 2022002498A PE 2022002498 A PE2022002498 A PE 2022002498A PE 20230488 A1 PE20230488 A1 PE 20230488A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- alkyl
- independently
- halo
- compounds
- Prior art date
Links
- 102000001235 protein arginine deiminase Human genes 0.000 title abstract 4
- 108060006632 protein arginine deiminase Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 abstract 1
- 101150094373 Padi4 gene Proteins 0.000 abstract 1
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Referido a un compuesto de Formula I, o una sal, estereoisomero, mezcla de estereoisomeros, o tautomero farmaceuticamente aceptable del mismo, en donde: X1 y X2 son C o N; X3 es N-R3 o C-R3; siempre que dos de X1, X2, y X3 son C; X4 es N o C-R2; X5 es N o CR6; X7 es N o CR7; R1 es H, halo, -CN, -OR12, entre otros; L1, L2, L3, L4, L5, y L6 son cada uno independientemente: alquileno C1-10, opcionalmente sustituido con 1 a 3 Z8; alquenileno C2-10, opcionalmente sustituido con 1 a 3 Z8; entre otros; m1, m2, m3, m4, m5, y m6 son cada uno independientemente 0 o 1; R10 es H, -alquilo C1-8 opcionalmente sustituido con 1 a 3 Z10, o cicloalquilo C3-6 opcionalmente sustituido con 1 a 3 Z10; R11 es H, -alquilo C1-8 opcionalmente sustituido con 1 a 4 Z11, -cicloalquilo C3-8 opcionalmente sustituido con 1 a 4 Z11, entre otros; cada Z10 y Z11 se selecciona independientemente de oxo, halo, -CN, alquilo C1-8 opcionalmente sustituido, entre otros. Estos compuestos son inhibidores macrociclicos de las peptidilarginina deiminasas (PAD). Tambien se refiere a procesos e intermediarios para la preparacion de tales compuestos, composicion farmaceutica que comprende dicho compuesto, un metodo para inhibir PAD tipo 4 y su uso en el tratamiento de artritis reumatoide o una enfermedad o afeccion mediada por PAD4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063018411P | 2020-04-30 | 2020-04-30 | |
| US202063129430P | 2020-12-22 | 2020-12-22 | |
| PCT/US2021/029557 WO2021222353A1 (en) | 2020-04-30 | 2021-04-28 | Macrocyclic inhibitors of peptidylarginine deiminases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230488A1 true PE20230488A1 (es) | 2023-03-21 |
Family
ID=76181198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002498A PE20230488A1 (es) | 2020-04-30 | 2021-04-28 | Inhibidores macrociclicos de las peptidilarginina deiminasas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11976083B2 (es) |
| EP (1) | EP4143189A1 (es) |
| JP (1) | JP7507251B2 (es) |
| KR (1) | KR20230004810A (es) |
| CN (1) | CN115551862B (es) |
| AU (1) | AU2021265110B2 (es) |
| BR (1) | BR112022021963A2 (es) |
| CA (1) | CA3177532A1 (es) |
| CL (1) | CL2022002990A1 (es) |
| CO (1) | CO2022015307A2 (es) |
| CR (1) | CR20220550A (es) |
| DO (1) | DOP2022000235A (es) |
| IL (1) | IL296923A (es) |
| MX (1) | MX2022013615A (es) |
| PE (1) | PE20230488A1 (es) |
| TW (1) | TWI815110B (es) |
| WO (1) | WO2021222353A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220109408A (ko) | 2019-11-04 | 2022-08-04 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| US12240862B2 (en) | 2020-12-22 | 2025-03-04 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| TW202241884A (zh) | 2020-12-22 | 2022-11-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
| AU2022387714A1 (en) | 2021-11-15 | 2024-05-30 | Regor Pharmaceuticals, Inc. | Pad4 inhibitors and use thereof |
| WO2024008745A1 (en) | 2022-07-05 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Methods and composition to identify and treat subjects resisting to chemotherapy treatment |
| CN115960124B (zh) * | 2023-02-23 | 2025-02-18 | 康化（上海）新药研发有限公司 | 一种2-氟-3-甲酰基-吡啶-4-硼酸频哪醇酯的合成方法 |
| WO2025024288A1 (en) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Heterocyclic pad4 inhibitors |
| WO2025024265A1 (en) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad4 modulators |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3821540A1 (de) | 1988-06-25 | 1989-12-28 | Boehringer Mannheim Gmbh | Neue sulfonamide, verfahren zu ihrer herstellung sowie solche sulfonamide enthaltende arzneimittel |
| DK2152701T3 (en) | 2007-03-12 | 2016-02-15 | Ym Biosciences Australia Pty | Phenylaminopyrimidinforbindelser and uses thereof |
| US8232274B2 (en) | 2007-03-15 | 2012-07-31 | Albany Molecular Research, Inc. | Pyridazinone derivatives useful as glucan synthase inhibitors |
| GB201106520D0 (en) | 2011-04-18 | 2011-06-01 | Numedicus Ltd | Pharmaceutical compounds |
| LT2877467T (lt) * | 2012-07-26 | 2017-01-10 | Glaxo Group Limited | 2-(azaindol-2-il)benzimidazolai, kaip pad4 inhibitoriai |
| ES2945314T3 (es) * | 2015-05-21 | 2023-06-30 | Glaxosmithkline Ip Dev Ltd | Derivados de benzoimidazol como inhibidores de PAD4 |
| AR107030A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
| AR107032A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| TW201825476A (zh) * | 2016-02-23 | 2018-07-16 | 扣鎖醫療公司 | Pad4之雜芳基抑制劑 |
| US10703741B2 (en) * | 2016-07-27 | 2020-07-07 | Padlock Therapeutics, Inc. | Covalent inhibitors of PAD4 |
| ES2924522T3 (es) | 2016-09-12 | 2022-10-07 | Padlock Therapeutics Inc | Inhibidores heteroarilo de PAD4 |
| JP7269919B2 (ja) | 2017-09-21 | 2023-05-09 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ターゲット薬剤サンプルの固体フラクションを評価するための固体フラクションセンサーの使用、および固体フラクションセンサー |
| US11833156B2 (en) | 2017-09-22 | 2023-12-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| WO2019077631A1 (en) * | 2017-10-18 | 2019-04-25 | Jubilant Biosys Limited | IMIDAZO-PYRIDINE COMPOUNDS FOR USE AS PAD INHIBITORS |
| US11453676B2 (en) | 2018-02-02 | 2022-09-27 | Forward Therapeutics, Inc. | Inhibitors of protein arginine deiminases |
| JP2021515043A (ja) * | 2018-02-26 | 2021-06-17 | 南京薬捷安康生物科技有限公司Ｎａｎｊｉｎｇ Ｔｒａｎｓｔｈｅｒａ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏ．， Ｌｔｄ． | ペプチジルアルギニンデイミナーゼ阻害剤及びその使用 |
| EP3833671B1 (en) | 2018-08-08 | 2022-08-24 | Bristol-Myers Squibb Company | Substituted thienopyrroles as pad4 inhibitors |
| SG11202101176YA (en) | 2018-08-08 | 2021-03-30 | Bristol Myers Squibb Co | Substituted benzimidazoles as pad4 inhibitors |
| CN112789087B (zh) | 2018-08-08 | 2024-08-13 | 百时美施贵宝公司 | Pad酶的苯并咪唑抑制剂 |
| WO2020033520A1 (en) * | 2018-08-08 | 2020-02-13 | Bristol-Myers Squibb Company | Indole and azaindole inhibitors of pad enzymes |
| WO2021061803A1 (en) | 2019-09-23 | 2021-04-01 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
| WO2021057910A1 (zh) | 2019-09-27 | 2021-04-01 | 南京药捷安康生物科技有限公司 | 肽酰精氨酸脱亚胺酶抑制剂及其用途 |
| KR20220137694A (ko) * | 2020-02-06 | 2022-10-12 | 브리스톨-마이어스 스큅 컴퍼니 | 면역억제제로서 유용한 마크로시클릭 pad4 억제제 |
| TW202140477A (zh) | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環ｐａｄ４抑制劑 |
-
2021
- 2021-04-28 EP EP21728673.1A patent/EP4143189A1/en active Pending
- 2021-04-28 WO PCT/US2021/029557 patent/WO2021222353A1/en not_active Ceased
- 2021-04-28 KR KR1020227041633A patent/KR20230004810A/ko active Pending
- 2021-04-28 CR CR20220550A patent/CR20220550A/es unknown
- 2021-04-28 US US17/242,617 patent/US11976083B2/en active Active
- 2021-04-28 JP JP2022566059A patent/JP7507251B2/ja active Active
- 2021-04-28 AU AU2021265110A patent/AU2021265110B2/en active Active
- 2021-04-28 CN CN202180030878.8A patent/CN115551862B/zh active Active
- 2021-04-28 BR BR112022021963A patent/BR112022021963A2/pt not_active Application Discontinuation
- 2021-04-28 PE PE2022002498A patent/PE20230488A1/es unknown
- 2021-04-28 IL IL296923A patent/IL296923A/en unknown
- 2021-04-28 CA CA3177532A patent/CA3177532A1/en active Pending
- 2021-04-28 MX MX2022013615A patent/MX2022013615A/es unknown
- 2021-04-29 TW TW110115682A patent/TWI815110B/zh active
-
2022
- 2022-10-27 CL CL2022002990A patent/CL2022002990A1/es unknown
- 2022-10-27 CO CONC2022/0015307A patent/CO2022015307A2/es unknown
- 2022-10-27 DO DO2022000235A patent/DOP2022000235A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3177532A1 (en) | 2021-11-04 |
| DOP2022000235A (es) | 2022-11-30 |
| CL2022002990A1 (es) | 2023-07-14 |
| AU2021265110A1 (en) | 2022-10-27 |
| KR20230004810A (ko) | 2023-01-06 |
| BR112022021963A2 (pt) | 2022-12-13 |
| JP2023524036A (ja) | 2023-06-08 |
| US11976083B2 (en) | 2024-05-07 |
| CN115551862B (zh) | 2024-04-12 |
| TWI815110B (zh) | 2023-09-11 |
| EP4143189A1 (en) | 2023-03-08 |
| IL296923A (en) | 2022-12-01 |
| WO2021222353A1 (en) | 2021-11-04 |
| US20230002412A1 (en) | 2023-01-05 |
| CO2022015307A2 (es) | 2023-02-16 |
| MX2022013615A (es) | 2022-11-16 |
| JP7507251B2 (ja) | 2024-06-27 |
| TW202206431A (zh) | 2022-02-16 |
| CR20220550A (es) | 2022-12-15 |
| CN115551862A (zh) | 2022-12-30 |
| AU2021265110B2 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230488A1 (es) | Inhibidores macrociclicos de las peptidilarginina deiminasas | |
| CL2022001739A1 (es) | Compuestos tricíclicos sustituidos | |
| CO2022008997A2 (es) | Compuestos tricíclicos sustituidos | |
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| CO2022002804A2 (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| AR065654A1 (es) | 3-ciano-4-(4-tetrahidropiran-fenil)-piridin-2-ona derivados,composiciones farmaceuticas que los contienen,metodo de preparacion de los mismos,y usos para prevenir o tratar trastornos neurologicos y psiquiatricos. | |
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
| PE20251179A1 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| AR068512A1 (es) | Derivados de 4-aril-1h-piridin-2-onas disustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central | |
| AR111878A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO6361925A2 (es) | Nuevos compuestos utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| AR094966A1 (es) | Composiciones farmacéuticas para el tratamiento de infecciones hcv | |
| AR071369A1 (es) | Compuesto de 1- ciano-3-pirrolidinil-n-sustituido-sulfonamida, su uso para preparar un medicamento util para tratar una enfermedad pulmonar obstructiva cronica y composicion farmaceutica que lo comprende | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| PE20241307A1 (es) | Inhibidores de molecula pequena de proteasa 1 especifica de ubiquitina (usp1) y usos de los mismos | |
| CA3151865A1 (en) | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as nlpr3 modulators for the treatment of multiple sclerosis (ms) | |
| PE20240652A1 (es) | Compuestos que inhiben la isoforma alfa de pi3k y metodos para tratar el cancer | |
| PE20201280A1 (es) | Amidas de imidazopiridina sustituidas y su uso | |
| AR095310A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CA3147571A1 (en) | Nlrp3 modulators | |
| PE20251667A1 (es) | Compuestos ciclicos de urea tiazolilo para el tratamiento del hsv |